KR101016838B1 - 로티고틴 투여를 위한 향상된 경피 송달 시스템 - Google Patents

로티고틴 투여를 위한 향상된 경피 송달 시스템 Download PDF

Info

Publication number
KR101016838B1
KR101016838B1 KR1020057001233A KR20057001233A KR101016838B1 KR 101016838 B1 KR101016838 B1 KR 101016838B1 KR 1020057001233 A KR1020057001233 A KR 1020057001233A KR 20057001233 A KR20057001233 A KR 20057001233A KR 101016838 B1 KR101016838 B1 KR 101016838B1
Authority
KR
South Korea
Prior art keywords
rotigotine
tds
matrix
adhesive
silicone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020057001233A
Other languages
English (en)
Korean (ko)
Other versions
KR20050056942A (ko
Inventor
마이크한네이
디트리스윌헬름스챠슈트
한스-마이켈울푸
Original Assignee
유씨비 파르마 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유씨비 파르마 게엠베하 filed Critical 유씨비 파르마 게엠베하
Publication of KR20050056942A publication Critical patent/KR20050056942A/ko
Application granted granted Critical
Publication of KR101016838B1 publication Critical patent/KR101016838B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057001233A 2002-07-30 2003-07-28 로티고틴 투여를 위한 향상된 경피 송달 시스템 Expired - Lifetime KR101016838B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016860A EP1386605A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system for the administration of rotigotine
EP02016860.5 2002-07-30

Publications (2)

Publication Number Publication Date
KR20050056942A KR20050056942A (ko) 2005-06-16
KR101016838B1 true KR101016838B1 (ko) 2011-02-22

Family

ID=30011090

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057001233A Expired - Lifetime KR101016838B1 (ko) 2002-07-30 2003-07-28 로티고틴 투여를 위한 향상된 경피 송달 시스템

Country Status (19)

Country Link
EP (2) EP1386605A1 (https=)
JP (2) JP4837916B2 (https=)
KR (1) KR101016838B1 (https=)
CN (2) CN101953819A (https=)
AT (1) ATE322263T1 (https=)
AU (1) AU2003258539B2 (https=)
BR (1) BR0313091A (https=)
CA (1) CA2491366A1 (https=)
DE (1) DE60304477T2 (https=)
DK (1) DK1524975T3 (https=)
ES (1) ES2256780T3 (https=)
IL (1) IL165918A0 (https=)
MX (1) MXPA05000350A (https=)
NO (1) NO333297B1 (https=)
PL (1) PL217079B1 (https=)
PT (1) PT1524975E (https=)
SI (1) SI1524975T1 (https=)
WO (1) WO2004012730A1 (https=)
ZA (1) ZA200500252B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2006039532A2 (en) * 2004-09-29 2006-04-13 Schwarz Pharma, Inc. Transdermal therapeutic system for parkinson’s disease
US7353034B2 (en) 2005-04-04 2008-04-01 X One, Inc. Location sharing and tracking using mobile phones or other wireless devices
EP2349230A2 (en) * 2008-10-06 2011-08-03 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
US9925150B2 (en) * 2009-12-22 2018-03-27 Lts Lohmann Therapie-Systeme Ag Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
MX2012012069A (es) 2010-04-30 2012-11-22 Teikoku Pharma Usa Inc Composiciones transdermicas de propinilaminoindan.
KR101853082B1 (ko) 2011-03-24 2018-04-27 테이코쿠 팔마 유에스에이, 인코포레이티드 활성제층 및 활성제 변환층을 포함하는 경피 조성물
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
KR101558042B1 (ko) * 2012-07-05 2015-10-07 에스케이케미칼주식회사 로티고틴을 함유한 경피흡수제제
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
US20160199316A1 (en) 2013-06-14 2016-07-14 Tesa Labtec Gmbh Three-layer transdermal therapy system (tts)
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
EP3016641B1 (de) 2013-07-03 2018-09-05 LTS Lohmann Therapie-Systeme AG Transdermales therapeutisches system mit elektronischem bauteil
EP3145502B1 (en) 2014-05-20 2022-07-06 LTS Lohmann Therapie-Systeme AG Transdermal delivery system containing rotigotine
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
WO2015177209A1 (en) * 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
KR102364378B1 (ko) 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
CN104382850B (zh) * 2014-10-17 2017-12-22 烟台大学 一种罗替戈汀微乳及微乳凝胶
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007468A1 (en) * 1992-10-05 1994-04-14 Cygnus Therapeutic Systems Two-phase matrix for sustained release drug delivery device
KR20010042336A (ko) * 1998-03-30 2001-05-25 베헤르, 베슬링 디2-효현제를 포함하는 파킨슨 증후군을 치료하기 위해제공된 경피 치료 시스템 및 그 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
EP1256340B1 (en) * 2001-05-08 2003-08-13 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007468A1 (en) * 1992-10-05 1994-04-14 Cygnus Therapeutic Systems Two-phase matrix for sustained release drug delivery device
KR20010042336A (ko) * 1998-03-30 2001-05-25 베헤르, 베슬링 디2-효현제를 포함하는 파킨슨 증후군을 치료하기 위해제공된 경피 치료 시스템 및 그 제조 방법

Also Published As

Publication number Publication date
ES2256780T3 (es) 2006-07-16
PL374814A1 (en) 2005-10-31
CN101953819A (zh) 2011-01-26
CN1671375A (zh) 2005-09-21
DE60304477D1 (de) 2006-05-18
JP2011219485A (ja) 2011-11-04
MXPA05000350A (es) 2005-03-31
EP1524975B9 (en) 2012-02-22
JP2005535687A (ja) 2005-11-24
AU2003258539A1 (en) 2004-02-23
PL217079B1 (pl) 2014-06-30
EP1524975A1 (en) 2005-04-27
WO2004012730A1 (en) 2004-02-12
KR20050056942A (ko) 2005-06-16
ATE322263T1 (de) 2006-04-15
EP1386605A1 (en) 2004-02-04
AU2003258539B2 (en) 2008-08-21
NO20050472L (no) 2005-01-27
DE60304477T2 (de) 2006-12-14
CA2491366A1 (en) 2004-02-12
JP4837916B2 (ja) 2011-12-14
SI1524975T1 (sl) 2006-06-30
EP1524975B1 (en) 2006-04-05
NO333297B1 (no) 2013-04-29
PT1524975E (pt) 2006-07-31
JP5564469B2 (ja) 2014-07-30
DK1524975T3 (da) 2006-07-31
ZA200500252B (en) 2006-01-25
IL165918A0 (en) 2006-01-15
BR0313091A (pt) 2005-06-21

Similar Documents

Publication Publication Date Title
KR101016838B1 (ko) 로티고틴 투여를 위한 향상된 경피 송달 시스템
US8617591B2 (en) Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) Transdermal delivery system
KR101016914B1 (ko) 향상된 경피 송달 시스템
HK1062649A (en) Improved transdermal delivery system
HK1062650A (en) Improved transdermal delivery system for the administration of rotigotine
HK1083458B (en) Improved transdermal delivery system
HK1083459A (en) Improved transdermal delivery system for the administration of rotigotine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080509

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100608

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20101213

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20110215

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20110215

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140121

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140121

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20150119

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150119

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160119

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160119

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170119

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170119

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20180118

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20180118

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20190116

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20190116

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20200115

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20200115

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20210115

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20230117

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20240128

Termination category: Expiration of duration